ENTA vs. ANAB, TSHA, ORGO, TBPH, MAZE, MRVI, KROS, BCAX, RLAY, and TYRA
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include AnaptysBio (ANAB), Taysha Gene Therapies (TSHA), Organogenesis (ORGO), Theravance Biopharma (TBPH), Maze Therapeutics (MAZE), Maravai LifeSciences (MRVI), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), Relay Therapeutics (RLAY), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry.
Enanta Pharmaceuticals vs. Its Competitors
Enanta Pharmaceuticals (NASDAQ:ENTA) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.
Enanta Pharmaceuticals has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500.
Enanta Pharmaceuticals has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Enanta Pharmaceuticals had 3 more articles in the media than AnaptysBio. MarketBeat recorded 6 mentions for Enanta Pharmaceuticals and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.90 beat Enanta Pharmaceuticals' score of 0.32 indicating that AnaptysBio is being referred to more favorably in the news media.
95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 13.9% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 33.5% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
AnaptysBio has a net margin of -107.66% compared to Enanta Pharmaceuticals' net margin of -141.98%. Enanta Pharmaceuticals' return on equity of -89.02% beat AnaptysBio's return on equity.
Enanta Pharmaceuticals currently has a consensus price target of $21.67, suggesting a potential upside of 145.38%. AnaptysBio has a consensus price target of $46.13, suggesting a potential upside of 128.12%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than AnaptysBio.
Summary
Enanta Pharmaceuticals beats AnaptysBio on 10 of the 17 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ENTA) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access